Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 73, No 2 (2023)
Review paper
Published online: 2023-04-27
View PDF Download PDF file
Get Citation

Osteoporosis – a partially recognized challenge for oncology

Krzysztof Jeziorski12
DOI: 10.5603/NJO.2023.0018
·
Nowotwory. Journal of Oncology 2023;73(2):85-90.
Affiliations
  1. Department of Gerontology, Public Health and Didactics, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
  2. Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Vol 73, No 2 (2023)
Review article
Published online: 2023-04-27

Abstract

Osteoporosis is a huge challenge for medicine, especially public health and geriatrics, but also oncology, because it is a chronic disease requiring long-term, sometimes lifelong care. With the ageing of the population, falls are the third most common cause of disability in the elderly and one of the main reasons for admissions to nursing homes. Although there are approximate data on the incidence of osteoporosis worldwide, there are unfortunately no data on the incidence of osteoporosis in cancerous diseases. The incidence of cancer-related osteoporosis is expected to increase as the inci­dence of cancer in general increases. There are specific problems that concern osteoporosis in cancer patients, including: the mechanisms of development of osteoporosis in cancer diseases, the distinction between cancerous and osteoporotic lesions, undertreatment of patients, the lack of an integrated care system for osteoporosis in cancer patients.

Abstract

Osteoporosis is a huge challenge for medicine, especially public health and geriatrics, but also oncology, because it is a chronic disease requiring long-term, sometimes lifelong care. With the ageing of the population, falls are the third most common cause of disability in the elderly and one of the main reasons for admissions to nursing homes. Although there are approximate data on the incidence of osteoporosis worldwide, there are unfortunately no data on the incidence of osteoporosis in cancerous diseases. The incidence of cancer-related osteoporosis is expected to increase as the inci­dence of cancer in general increases. There are specific problems that concern osteoporosis in cancer patients, including: the mechanisms of development of osteoporosis in cancer diseases, the distinction between cancerous and osteoporotic lesions, undertreatment of patients, the lack of an integrated care system for osteoporosis in cancer patients.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

osteoporosis; bone fracture; densitometry; malignant diseases

About this article
Title

Osteoporosis – a partially recognized challenge for oncology

Journal

Nowotwory. Journal of Oncology

Issue

Vol 73, No 2 (2023)

Article type

Review paper

Pages

85-90

Published online

2023-04-27

Page views

1815

Article views/downloads

195

DOI

10.5603/NJO.2023.0018

Bibliographic record

Nowotwory. Journal of Oncology 2023;73(2):85-90.

Keywords

osteoporosis
bone fracture
densitometry
malignant diseases

Authors

Krzysztof Jeziorski

References (41)
  1. Tom S, Adachi J, Anderson F, et al. Jr, Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc. 2013; 61(3): 327–334.
    CrossRefPubMed
  2. Blain H, Miot S, Bernard PL. How can we prevent falls? In: Falaschi PL, Marsh D. ed. Orthogeriatrics. The management of older patients with fragility fractures. Ed. 1. Springer, Roma. London 2021: 273–290.
  3. EuroSafe, Amsterdam (2015) Falls among older adults in the EU-28: key facts from the available statistics. https://eupha.org/repository/sections/ipsp/Factsheet_falls_in_older_adults_in_EU.pdf.
  4. Adami S, Bertoldo F, Brandi ML, et al. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo. 2009; 61(4): 260–284.
    CrossRefPubMed
  5. Kanis J, McCloskey E, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013; 24(1): 23–57.
    CrossRefPubMed
  6. Falaschi P, Marques A, Giordano S. Osteoporosis and fragility in elderly patients. In: Falaschi P, Marsh D. ed. Orthogeriatrics. The management of older patients with fragility fractures. Ed. 1. Springer, Roma. London 2021: 35–52.
  7. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6): 646–650.
    CrossRefPubMed
  8. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 321–322.
  9. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 89–92.
  10. Kanis J, Borgstrom F, Laet CDe, et al. Assessment of fracture risk. Osteoporos Int. 2004; 16(6): 581–589.
    CrossRef
  11. https://ezdrowie.gov.pl/5583?modId=37203.
  12. WHO. Approached February 1, 2020. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
  13. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8(1): 136.
    CrossRefPubMed
  14. Wojciechowska U, Barańska K, Michałek I, et al. Cancer in Poland in 2020.Polish National Cancer Registry. Warszawa 2022. https://onkologia.org.pl/sites/default/files/publications/2023-01/nowotwory_2020.pdf.
  15. Veronese N, Kolk H, Maggi S. Epidemiology of fragility fractures and social impact. In: Falaschi P, Marsh D. ed. Orthogeriatrics. The management of older patients with fragility fractures. Ed. 1. Springer, Roma. London 2021: 19–33.
  16. Drake MT. Osteoporosis and cancer.\. Curr Osteoporos Rep. 2013; 11(3): 163–170.
    CrossRefPubMed
  17. Bono CM, Einhorn TA. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J. 2003; 12 Suppl 2(Suppl 2): S90–S96.
    CrossRefPubMed
  18. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 413–416.
  19. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 409–411.
  20. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 389–397.
  21. Ramin C, May BJ, Roden RBS, et al. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study. Breast Cancer Res. 2018; 20(1): 134.
    CrossRefPubMed
  22. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 451–461.
  23. Coleman RE, Rubens RD. Bone metastases. In: Abeloff MD, Armitage JO, Niederhuber JE, et al. ed. Clinical Oncology. Ed. 3. Elsevier Churchill Livingstone, Philadelphia 2004: 1091–1128.
  24. Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Clinical Guidelines Committee of the American College of Physicians. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023; 176(2): 224–238.
    CrossRefPubMed
  25. Hildebrand GK, Kasi A. Denosumab. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Jan. 2022 Feb 24.
    PubMed
  26. Akel M, Parmar M. Abaloparatide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Jan. 2023 Jan 17.
    PubMed
  27. Merlotti D, Falchetti A, Chiodini I, et al. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019; 20(7): 805–811.
    CrossRefPubMed
  28. Canalis E. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis. Eur J Endocrinol. 2018; 178(2): R33–R44.
    CrossRefPubMed
  29. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40(6): 1434–1446.
    CrossRefPubMed
  30. Prather C, Adams E, Zentgraf W. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis. Am J Health Syst Pharm. 2020; 77(23): 1949–1956.
    CrossRefPubMed
  31. Muchmore DB. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist. 2000; 5(5): 388–392.
    CrossRefPubMed
  32. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393(10169): 364–376.
    CrossRefPubMed
  33. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122(2 Suppl): S3–13.
    CrossRefPubMed
  34. Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010; 21(11): 1943–1951.
    CrossRefPubMed
  35. Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014; 29(9): 1929–1937.
    CrossRefPubMed
  36. Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011; 6: 59–155.
    CrossRefPubMed
  37. Greenspan SL, Wyman A, Hooven FH, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatri Soc. 2012; 60(3): 455–461.
    CrossRefPubMed
  38. Kim SC, Kim MS, Sanfélix-Gimeno G, et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med. 2015; 128(5): 519–526.e1.
    CrossRefPubMed
  39. van der Velde RY, Wyers CE, Teesselink E, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity. Bone. 2017; 94: 50–55.
    CrossRefPubMed
  40. Walters S, Khan T, Ong T, et al. Fracture liaison services: improving outcomes for patients with osteoporosis. Clin Interv Aging. 2017; 12: 117–127.
    CrossRefPubMed
  41. Bonanni S, Sorensen AA, Dubin J, et al. The Role of the Fracture Liaison Service in Osteoporosis Care. Mo Med. 2017; 114(4): 295–298.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl